Study of prescribing pattern of drugs in the management of migraine with psychiatric comorbidities at integral institute of medical science and research

Authors

  • Abubakar Mustapha Department of Pharmacy Practice, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Kamran Khan Department of Pharmacy Practice, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Mantasha Yusuf Department of Pharmacy Practice, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Amir Abbas Department of Pharmacy Practice, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Mudassir Sada Department of Pharmacy Practice, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Badruddeen Faculty of Pharmacy, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • M. Yasir Ajmal Faculty of Pharmacy, Integral University, Kursi Road, Lucknow, Uttar Pradesh, India
  • Azhar Mahmood Farooaqui Department of Psychiatry, Integral Institute of Medical Sciences and Research, Kursi Road, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243032

Keywords:

Antidepressants, Anxiety, Depression, Migraine, NSAIDs, Psychiatric comorbidities

Abstract

Background: Migraine headaches, a prevalent and serious brain condition, often coincide with mental health issues. This study aims to explore drug prescribing patterns for migraine patients with psychiatric comorbidities.

Methods: Over six months, a prospective observational study was conducted at the psychiatric department of IIMS&R Hospital. 100 prescriptions were analyzed based on specific criteria.

Results: Total 14 different drugs were prescribed. NSAIDs were most common (87%), followed by multivitamins (50%), benzodiazepines (30%), and tricyclic antidepressants (23%).Naxdom (NSAIDs) was frequently used (87%). Patients aged 31-45 years had higher prevalence. Comorbidities associated are depression (18%), anxiety disorder (10%), insomnia (5%).

Conclusions: The study highlights various orally administered drugs, including anti-migraine meds, antidepressants, anticonvulsants, and more. Patients within the 31-45years age group were significantly affected. Migraine correlated with depression, anxiety, and insomnia. The most common medication was naxdom 250mg taken orally.

References

Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB, et al. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2018;260:1960-1969.

Cosci F, Svicher A, Mansueto G, Benemei S, Chiarugi A, De Cesaris F, et al. Mental pain and pain-proneness in patients with migraine: results from the PAINMIG cohort-study. CNS Spectrums. 2021;26(5):491-500.

Pietrobon D, Moskowitz MA. The cerebral circulation in migraine: From pathophysiology to anti-migraine treatments. Nature Reviews Neurosci. 2020;21(1):19-33.

Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front. Neurol. 2022;12:800605.

Rose FC. The history of migraine from Mesopotamian to Medieval times. Cephalalgia. 1995;15(15_suppl):1-3.

Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia. 2005;25(3):165-78.

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Revi. 2017;97(2):553-622.

Smitherman TA, McDermott MJ, Buchanan EM. Negative impact of episodic migraine on a university population: quality of life, functional impairment, and comorbid psychiatric symptoms. Headache: J Head Face Pain. 2011;51(4):581-9.

Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001;85(4):911-4.

Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394-402.

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurol. 2007;68(5):343-9.

Baskin SM, Smitherman TA. Migraine and psychiatric disorders: Comorbidities, mechanisms, and treatment considerations. Headache: The Journal of Head and Face Pain, 2021;61(5):727-41.

Bhatia MS, Gupta R. Migraine: Clinical Pattern and psychiatric comorbidity. Ind Psychiatry J. 2012;21(1):18-21.

Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders- a national population-based study. Headache. 2008;48(4):501-16.

Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. The Lancet. 2021;397(10283):1485-95.

Merikangas KR, Risch NJ, Merikangas JR, Weissman MM, Kidd KK. Migraine and depression: association and familial transmission. J Psychiatr Res. 1988;22(2):119-29.

Rossi P, Di Lorenzo G, Malpezzi MG, Di Lorenzo C, Cesarino F, Faroni J, et al. Depressive symptoms and insecure attachment as predictors of disability in a clinical population of patients with episodic and chronic migraine. Headache. 2005;45(6):561-70.

Zwart JA, Dyb G, Hagen K, Ødegård KJ, Dahl AA, Bovim G, Stovner LJ, et al. Depression and anxiety disorders associated with headache frequency. The nord-trøndelag health study. Eur J Neurol. 2003;10(2):147-52.

Dresler T, Caratozzolo S, Guldolf K. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Head Pain. 2019;20(1):2019.

Evans RW, Rosen N. Expert opinion: migraine, psychiatric comorbidities, and treatment. Headache. 2008 Jun;48(6):952-8.

Devoto M, Lozito A, Staffa G, D'Alessandro R, Sacquegna T, Romeo G, et al. Segregation analysis of migraine in 128 families. Cephalalgia. 1986;6(2):101-5.

de Vries B, Anttila V, Freilinger T, Wessman M, Kaunisto MA, Kallela M, et al. Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia. 2016;36(7):604-14.

Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache. 2000;40(10):818-23.

Minen MT, Begasse De Dhaem O, Kroon Van Diest A. Comorbid psychiatric conditions impact on the burden and treatment of migraine. J Neurol Neurosurg Psychiatry 2016;87:741–749.

Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clinics. 2009;27(2):321-34.

Turner DP, Smitherman TA, Martin VT, Penzien DB, Houle TT. Causality and headache triggers. Headache: The Journal of Head and Face Pain. 2013;53(3):573-83.

Blau JN. Premonitory symptoms of migraine. In: Olesen J, Edvinson L, editors. Basic mechanisms of Headache. New York: Elsevier. 1988;345-51.

Peterlin BL, Tietjen G, Meng S, Lidicker J, Bigal M. Posttraumatic stress disorder in episodic and chronic migraine. Headache. 2008;48(4):517-22.

Antonaci F, Nappi G, Galli F. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011;12:115-25.

Ahmad A, Tausif M, Biswas N, Siddiqui A, Akhter MS, Khan N, et al. Drug utilization pattern for acne vulgaris in the department of dermatology at integral institute of medical science and research. Eur Chem Bull. 2023;12(10):6279-89.

Naqvi SAH, Ahmad MAF, Sohel MMA, Yadav A, Singh A, Ahmed J, et al. Drug utilization pattern and adverse drug reaction monitoring of antibiotics use in ear, nose and throat infection at tertiary care hospital, Lucknow, India. Eur PMC. 2023:1-8.

Mujahid M, Sharma M, Aqil M, Iqbal D, Kapur P. Drug utilization and adverse drug reaction monitoring in NSAID Users in a South Delhi Hospital. Int J Res Pharm Chem. 2012;1(3).

Kumar S, Badruddeen, Singh SP, Akhtar J, Khan MI, Ahmad M, Ahmad U. Assessment of analgesics induced adverse drug reactions in a tertiary care hospital. 2020;13(10)-4861-4.

Khushtar, Singh M, Ajmal M, Javed MS, Siddique F, Shams AR, et al. Drug utilization pattern and adverse drug reaction monitoring of drugs used in typhoid at a tertiary care hospital: a prospective study. World J Pharm Pharm Sci. 2023;12(7):1.

Ismail H, Fayaz F. Psychiatric comorbidity in patients with migraine. Int J Adv Med. 2022;9:924-7.

Vivek K, Nimish G, Saurabh S. Prevalence of psychiatric comorbidity in subjects with migraine: a hospital based study in western UP. IOSR-JDMS. 2017;16(10):56-60.

Banday M, Wani M, Farooq U, Parra B, Rather Y. Sociodemographic and comorbidity profiles of migraine patients: an outpatient-based study in a tertiary care hospital. Asian J Pharm Clin Res. 2020;13(8):59-64.

Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache: J Head Face Pain. 2019;59(3):306-38.

Balamurali KB, Prabhu KV, Thangaraj M, Meenakshi I, Arun Kumar M. Psychiatric co-morbidities in patients presenting with headache: a prospective study. J Med Sci Res. 2018;6(5):624-31.

Downloads

Published

2024-10-23

How to Cite

Mustapha, A., Khan, K., Yusuf, M., Abbas, A., Sada, M., Badruddeen, Ajmal, M. Y., & Farooaqui, A. M. (2024). Study of prescribing pattern of drugs in the management of migraine with psychiatric comorbidities at integral institute of medical science and research. International Journal of Basic & Clinical Pharmacology, 13(6), 843–848. https://doi.org/10.18203/2319-2003.ijbcp20243032

Issue

Section

Original Research Articles